Search results
Spontaneous Persistent Inactivity – Scientists Discover New Type of Memory State
SciTechDaily· 2 hours agoUCLA Health research identifies a new memory state called spontaneous persistent inactivity. UCLA...
How Does Alzheimer’s Kill?
MedicineNet.com· 4 days agoAlzheimer's disease (AD) is a degenerative disease of the brain, resulting in memory loss, cognitive decline, and personality changes ...
Alzheimer’s biomarkers observed in young people with diabetes
MedicalNewsToday via AOL· 15 hours agoNew research shows that adolescents and young adults with type 1 or type 2 diabetes may be at higher...
Eisai initiates rolling Biologics License Application to US FDA for Leqembi® (lecanemab-irmb) for...
FOX 59 Indianapolis· 4 hours agoIn the US, Leqembi is indicated for the treatment of Alzheimer's disease (AD) in patients with Mild...
Unauthorized Living Season 1 Streaming: Watch & Stream Online via Netflix
COMINGSOON.net via Yahoo News· 3 hours agoThe show revolves around Nemo Bandeira, a powerful drug lord. After getting diagnosed with Alzheimer...
...Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast...
NBC 10 - FOX 14 Monroe· 8 hours agoLEQEMBI is indicated for the treatment of Alzheimer's disease (AD) in patients with Mild Cognitive Impairment (MCI) or mild dementia ...
'I'm a Neurologist, and This Is My Go-To Dinner For Alzheimer's Prevention'
Parade via Yahoo News· 4 days agoNeurologist cooking dinner for Alzheimer's prevention Nearly 7 million Americans are living with ...
ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights
Digital Journal· 11 hours agoTop-line data from first-in-human Phase 1a clinical trial of PMN310 as a treatment for Alzheimer’s disease on track for mid-2024CAMBRIDGE ...
LIVING WELL: New drug approved to treat Alzheimer’s Disease
FOX 16 Little Rock· 1 day agoThe FDA approved a new drug to treat Alzheimer’s Disease.
Halia Therapeutics to Unveil New Clinical Program Targeting the LRRK2 Protein for Alzheimer's ...
The Herald Journal· 19 hours agoCEO David J. Bearss, Ph.D., will be participating in a panel discussing the "Landscape of Drug Discovery and Impact of AI Discussion" on Wednesday, May 22, from 1:50 to 2:30